Introduction
Valproic acid (VPA) is a major antiepileptic drug with efficacy against multiple seizure types ( Simon and Penry, 1975) . Valproic acid is well known to affect mechanisms that control drug disposition, such as the activity of hepatic biotransformation enzymes or drug binding to plasma proteins (Rogiers et al., 1995; Wen et al., 2001; Perucca, 2006) . Regarding metabolizing enzymes of the cytochrome P450 family, there is clear evidence that valproic acid has the potential to up-regulate expression and activity of several rodent and human genes encoding proteins involved in drug disposition. Rogiers et al. (1992 Rogiers et al. ( , 1995 reported that valproic acid is a potent inducer of genes of the rat CYP2B subfamily, in particular CYP2B1/CYP2B2. Cerveny et al. (2007) recently reported that valproic acid has the potential to upregulate CYP3A4 and MDR1 through direct activation of the constitutive androstane receptor (CAR) and/or pregnane X receptor pathways. These data indicate that valproic acid is capable of altering the expression and activity of various P450s.
Phenobarbital (PB) and phenytoin, which are also antiepileptic drugs, induce CYP2B activity by activating the CAR (Honkakoski et al., 1998; Tzameli et al., 2000; Schuetz, 2001; Pascussi et al., 2003; Wang et al., 2004) . CAR is a ligand-activated nuclear receptor that forms heterodimers with retinoid X receptor (RXR) ␣ and up-regulates the transcription of target genes, such as CYP2B6 and UGT1A1, by interaction with specific promoter binding motifs Sugatani et al., 2001) . CAR is activated by many structurally and chemically diverse ligands. CAR activators include xenobiotics such as phenytoin (Wang et al., 2004), clotrimazole, chlorpromazine, 1,4-bis[2-(3,5-dichloropyridyloxy) ]benzene (TCPOBOP), and 6-(4-chlorophenyl) imidazo [2,1-b] [1,3]thiazole-5-carbaldehyde O- (3,4-dichlorobenzyl) oxime (Maglich et al., 2003) . However, the affinities of these activators for CAR vary with species, and, in many cases, they do not bind CAR directly Swales and Negishi, 2004) . -(3,4-dichlorobenzyl) oxime are the only compounds shown to specifically bind to mouse CAR and human CAR, respectively (Tzameli et al., 2000; Maglich et al., 2003) .
PB-induced, CAR-mediated induction of CYP2B genes is thought to occur by the activation of cytosolic CAR upon PB exposure, resulting in its dissociation from its co-chaperone partners, cytoplasmic CAR retention protein and heat shock protein 90 (Kobayashi et al., 2003) . The translocation of CAR to the nucleus, which is presumably dependent on the activity of protein phosphatase PP2A, is followed by association with the RXR and binding to the phenobarbitalresponsive enhancer module (PBREM) (Honkakoski et al., 1996; Kobayashi et al., 2003; Swales et al., 2005) . Transcriptional activation occurs upon CAR binding to the PBREM, which contains two nuclear receptor DR4 sites (NR1 and NR2).
Valproic acid is an inhibitor of histone deacetylases (HDACs), which are involved in the modulation of gene expression Krämer et al., 2003) among numerous other effects on diverse drug targets. Valproic acid has been shown to affect the expression of a large number of genes (Bosetti et al., 2004) . Some of these recognized alterations in gene expression have been attributed to HDAC inhibitory activity of valproic acid (Phiel et al., 2001; Werling et al., 2001; Eyal et al., 2006) . However, it is unclear whether valproic acid acts as an HDAC inhibitor or by means of some other mechanism to induce CYP2B forms.
The 18 HDACs identified in humans are classified in four classes, classes I to IV (Bertrand, 2010) . Classes I, II, and IV are zincdependent metalloproteins and class III is NAD ϩ -dependent (Bertrand, 2010). There are several differences in zinc-dependent classes I, II, and IV HDACs according to size (number of amino acids), cellular distribution, and known interactions with transcription factors (Ocker and Schneider-Stock, 2007) . HDAC1, 2, 3, and 8 define the class I group, which is mostly nuclear and smaller in size (350 -500 amino acids) (Ocker and Schneider-Stock, 2007) . There are selectivities of inhibition by HDAC inhibitors, and valproic acid inhibits class I HDACs.
In this study, we investigated whether HDAC inhibitors control expression of CYP2B6 genes at the transcriptional level via activation of CAR pathways using Ym17 cells (HepG2 cells that stably express CAR) (Sueyoshi et al., 1999; Swales et al., 2005) . The data indicate that HDAC inhibitors can activate CYP2B6 via interaction with the CAR pathway. Moreover, HDAC inhibitors synergize with the CAR ligand, TCPOBOP, in transactivation of CYP2B6 in Ym17 cells. HDAC inhibitors inhibit the binding between CAR and HDAC1 and recruit SRC-1 binding to CAR.
Materials and Methods
Materials. VPA, phenylbutyrate (PBA), trichostatin A (TSA), and TCPOBOP were purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals were obtained from commercial sources at the highest grade of purity available. Anti-V5 antibody was purchased from Invitrogen (Carlsbad, CA), anti-HDAC1 and anti-HDAC2 antibodies were purchased from Affinity BioRegents (Golden, CO), anti-His, anti-HDAC3, and anti-SRC-1 antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). PBREM-thymidine kinase (tk)-luciferase and (NR1) 5 -tk-luciferase (Sueyoshi et al., 1999) , Ϫ1.8k-pGL3 (Swales et al., 2005) reporter gene plasmids, were kindly provided by Dr. Masahiko Negishi (National Institute of Environmental Health Sciences, Research Triangle Park, NC). The complementary oligonucleotides of human PBREM and the five times human NR1 [(5Ј-gatcACTGTACTTTCCTGACCTTGgatc-3Ј) 5 ] sequences were cloned in front of the tk promoter (BglII site), resulting in PBREM-tk-luciferase and (NR1) 5 -tk-luciferase reporter gene plasmids (Sueyoshi et al., 1999) . The 1.8-kilobase pair 5Ј-flanking DNA of the CYP2B6 gene was cloned between the KpnI and XhoI sites of basic firefly luciferase reporter plasmid pGL3-Basic (Ϫ1.8k-pGL3) (Swales et al., 2005) .
Cell Culture and Transfection Assays. Ym17 cells, a stable cell line that expresses murine CAR, was established from HepG2 cells that were transfected with a mouse pcDNA3.1-CAR-V5-His expression vector and were selected for neomycin resistance (Swales et al., 2005) . Cells were cultured in minimal essential medium supplemented with 10% fetal bovine serum and antibiotics (100 units/ml penicillin and 100 g/ml streptomycin). Ym17 cells in 24-well plates were cotransfected with a luciferase reporter plasmid [PBREM, (NR1) 5 , Ϫ1.8k-pGL3] and pRL-SV40 plasmid (0.1 g/well each) by the calcium phosphate coprecipitation method using a CellPhect Transfection Kit (GE Healthcare, Little Chalfont, Buckinghamshire, UK) for transient transfection assays. Sixteen hours after transfection, the cells were treated with chemicals. Luciferase activity was measured in cell lysates using the dualluciferase reporter assay system (Promega, Madison, WI). The receptor-dependent enhancer activity was determined based on firefly luciferase activity normalized against Renilla luciferase activity.
Animals and Treatment. The CAR(ϩ/ϩ) and CAR(Ϫ/Ϫ) mice used in this study were C3H background mice as described previously (Yamamoto et al., 2004) . All mouse procedures were performed in accordance with the guidelines for animal care and use established by Gunma University Graduate School of Medicine. Germline transmission of the disrupted allele was detected by polymerase chain reaction (PCR) (Ueda et al., 2002) . Male mice from each genotype were given a single intraperitoneal injection of phenylbutyrate (1 g/kg) and/or TCPOBOP (1 mg/kg). The mice were then sacrificed, and their livers were collected and saved for analysis 6 h after intraperitoneal injection (n ϭ 5 per treatment group).
Reverse Transcription-Polymerase Chain Reaction. Total RNA was extracted from the Ym17 cells or mouse liver. The subsequent synthesis of first-strand cDNA was performed using TRIzol reagent (Invitrogen) and the SuperScript preamplification system (Invitrogen), respectively. cDNAs were amplified using the following sets of primers: CYP2B6 mRNA, 5Ј-AAGCG-GATTTGTCTTGGTGAA-3Ј and 5Ј-TGGAGGATGGTGGTGAAGAAG-3Ј; Cyp2b10 mRNA, 5Ј-CACCACGCTCCACTATGGCT-3Ј and 5Ј-CTGTGTG-GCACTCCAATAGGTATAA-3Ј; UGT1A1 mRNA, 5Ј-TTTTGTCTGGCT-GTTCCCACT-3Ј and 5Ј-GAAGGTCATGTGATCTGAATGAGA-3Ј; and Ugt1a1 mRNA, 5Ј-TCTGAGCCCTGCATCTATCTG-3Ј and 5Ј-CCCCA-GAGGCGTTGACATA-3Ј.
One-twentieth of each cDNA synthesized from 5 g of RNA was subjected to real-time PCR using SYBR Green dye (Applied Biosystems, Foster City, CA). The levels of target mRNA were normalized to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels, and the fold induction was calculated relative to the controls.
Immunoprecipitation and Western Blotting Analysis. Ym17 cells were treated with 0.1% dimethyl sulfoxide or 500 M VPA, 1 mM PBA, and 500 nM TSA for 1 h. Next, nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce Chemical, Rockford, IL) according to the manufacturer's protocol. For immunoprecipitation assays, anti-Hisagarose (protein G-agarose; Roche Diagnostics GmbH, Penzberg, Germany) was incubated with nuclear extracts for 2 h at 4°C, washed with immunoprecipitation buffer following the manufacturer's manual, and subjected to Western blot analysis with anti-HDAC1, HDAC2, HDAC3, SRC-1, and V5 (for V5-His-tagged CAR) antibodies. The blots were incubated with the secondary antibodies, and the immunoreactive bands were visualized using an enhanced chemiluminescence system (GE Healthcare).
siRNA Expression. siRNAs for HDAC1, HDAC2, and HDAC3 were obtained from Ambion (Austin, TX) using the Silencer Select Validated siRNA series (Applied Biosystems). HDAC siRNA or control siRNA (Silencer Select Negative Control 1 siRNA; Ambion) (each 12.5 pmol) was transfected into Ym17 cells in each well of six-well plates following the manufacturer's instructions. The cells were cultured for 24 h and treated with chemicals. mRNA expression of CYP2B6 was determined by real-time RT-PCR.
Chromatin Immunoprecipitation. Ym17 cells were incubated with PBA (1 mM) and/or TCPOBOP (250 nM) for 1 h. Chromatin immunoprecipitation was performed using the chromatin immunoprecipitation (ChIP) assay kit (Millipore Corporation, Billerica, MA), according to the manufacturer's instructions. Proteins and DNA were cross-linked with 1% formaldehyde in the medium for 20 min at 37°C. The cells were collected in 450 l of SDS lysis buffer containing protease inhibitors aprotinin (1 g/ml), phenylmethanesulfonyl fluoride (1 M), and pepstatin A (1 g/ml) and were sonicated 20 times for 30 s each time using a BIORUPTER apparatus (Cosomo Bio, Tokyo, Japan) following the manufacturer's instructions. The sonication was optimized as described in the ChIP assay kit instructions. The diluted lysates were precleared by incubation with 160 l of protein A-agarose salmon sperm slurry, 60 l of normal mouse IgG, and 0.05% bovine serum albumin for 2 h at 4°C. The agarose was collected by centrifugation at 100g for 2 min at 4°C. One milliliter of the cleared fraction was subjected to overnight immunopre- 
treatment group. The immunoprecipitated complexes were recovered, washed, and eluted. The cross-links were reversed, and proteins were digested as described in the manufacturer's protocol. A phenol chloroform-ethanol precipitation method purified the DNA with a final resuspension in 45 l of water. The DNA was amplified by real-time PCR using a specific primer set designed to the PBREM. The PBREM 5Ј-and 3Ј-primers were 5Ј-GGCTGCAATGAGCACCCAATCTTA-3Ј and 5Ј-GGAGGAGCAGACAAACAGTCCTAT-3Ј, respectively.
Data Analysis. All experimental data are shown as the mean Ϯ S.D. Differences were determined by a one-way factorial analysis of variance for each group. The level of significance for all statistical analyses was set at P Ͻ 0.05.
Results
HDAC Inhibitors Induce Expression of CYP2B6 mRNA and Luciferase Reporter. mRNA expression of CYP2B6 was determined using Ym17 cells (Swales et al., 2005) . Endogenous CYP2B6 gene expression was up-regulated 3.0-fold by valproic acid, 14.8-fold by phenylbutyrate, and 8.0-fold by trichostatin A, respectively (Fig. 1A) . The (NR1) 5 -tk-luciferase reporter plasmid was transfected into Ym17 cells to determine whether HDAC inhibitors activated CYP2B6 transcription. Valproic acid, phenylbutyrate, and trichostatin A enhanced luciferase reporter activity 4.7-, 16.8-, and 8.6-fold, respectively (Fig.  1B) . HDAC inhibitors also enhanced a luciferase reporter gene containing the Ϫ1.8k enhancer region of CYP2B6. Valproic acid, phenylbutyrate, and trichostatin A enhanced luciferase reporter activity 2.1-, 11.4-, and 2.1-fold, respectively (Fig. 1C) . The results obtained with the PBREM-tk-luciferase reporter were similar to those obtained with the (NR1) 5 -tk-luciferase reporter and the Ϫ1.8k-pGL3 luciferase reporter (data not shown).
UGT1A1 mRNA expression was determined to investigate the effect of HDAC inhibitors on other CAR target genes. HDAC inhibitors did not affect the mRNA expression of UGT1A1, even though UGT1A1 is a CAR target gene (Fig. 1D) . Activation of the CAR target gene by HDAC inhibitors was specific for CYP2B6 but not for UGT1A1.
Synergistic Activation of CYP2B6 mRNA and Promoter by HDAC Inhibitors in Combination with CAR Ligand, TCPOBOP.
The expression of CYP2B6 mRNA upon cotreatment with TCPOBOP and HDAC inhibitors was determined to investigate the effects of HDAC inhibitors on ligand-activated CAR. HDAC inhibitors synergistically augmented the effect of TCPOBOP in the transactivation of CYP2B6 mRNA in Ym17 cells ( Fig. 2A) . HDAC inhibitors also FIG. 1. Effects of HDAC inhibitors on the mRNA expression of CAR target genes and transactivation of CYP2B6 promoter. HepG2 cells stably expressing mouse CAR (Ym17) were exposed to HDAC inhibitors (500 M valproic acid, 1 mM phenylbutyrate, and 500 nM trichostatin A) for 24 h. mRNA expression of tested genes was determined using real-time RT-PCR and normalized to GAPDH mRNA expression. Ym17 cells were transiently transfected with (NR1) 5 -tk-luciferase or Ϫ1.8k-pGL3 luciferase reporter construct. A, CYP2B6 mRNA expression. B, (NR1) 5 -tkluciferase promoter assay. C, Ϫ1.8k-pGL3 luciferase promoter assay. D, UGT1A1mRNA expression. ‫,ء‬ P Ͻ 0.01. Ctrl, control.
HISTONE DEACETYLASE INHIBITORS ACTIVATE NUCLEAR RECEPTOR CAR
at ASPET Journals on January 7, 2018 dmd.aspetjournals.org Downloaded from synergistically enhanced the response of the (NR1) 5 -tk-luciferase reporter gene to TCPOBOP (Fig. 2B) .
HDAC Inhibitors Induce the Expression of Cyp2b10 mRNA in Wild-Type Mice but Not in CAR-Null Mice. mRNA expression of Cyp2b10 was determined using CAR(Ϫ/Ϫ) mice to investigate the mechanism in CYP2B induction with HDAC inhibitors in vivo. The mice were given a single intraperitoneal injection of phenylbutyrate. The Cyp2b10 mRNA was induced 24.4-fold by phenylbutyrate in CAR(ϩ/ϩ) mice and 811-fold by TCPOBOP (Fig. 2C) . However, such Cyp2b10 mRNA induction was not observed in CAR(Ϫ/Ϫ) mice (Fig. 2C) . The mRNA expression of Cyp2b10 was determined by cotreatment with TCPOBOP and phenylbutyrate. However, there was no synergistic augmentation in transactivation of Cyp2b10 mRNA between phenylbutyrate and TCPOBOP (Fig. 2C) .
On the other hand, Ugt1a1 mRNA expression was not induced by phenylbutyrate in either CAR(ϩ/ϩ) or CAR(Ϫ/Ϫ) mice (Fig. 2D) . As a result, the activation of CAR target genes by phenylbutyrate was specific for Cyp2b10, and it was not observed on Ugt1a1.
Effects of HDAC Inhibitors on Binding between HDACs, SRC-1, and CAR. Immunoprecipitation with tagged CAR was used to investigate the interaction between HDACs and CAR (Swales et al., 2005) . Ym17 cells were treated with HDAC inhibitors at the indicated concentration for 1 h. The tagged CAR was immunoprecipitated by His antibody. Binding between HDAC1 and CAR was inhibited by HDAC inhibitors although no differences were observed in HDAC2 and HDAC3 binding (Fig. 3A) . Inversely, TCPOBOP treatment augmented the binding between HDAC1 and CAR.
Immunoprecipitation with tagged CAR was used for Western blotting to investigate the interaction between SRC-1 and CAR. The binding between coactivator SRC-1 and CAR was increased by HDAC inhibitors (Fig. 3B) . HDAC inhibitors disrupted the binding of HDAC1 and CAR and then recruited SRC-1 binding to CAR.
siRNA Knockdown of HDAC1. siRNA knockdown of HDACs was investigated because HDAC inhibitors affected the binding between HDAC1 and CAR. siRNA knockdown of HDAC1 increased mRNA expression of CYP2B6 1.8-fold, although there were no differences in HDAC2 and HDAC3 siRNA knockdown (Fig. 3C) , which was consistent with results of the immunoprecipitation experiments.
Binding to CAR Response Elements of CYP2B6 Investigated with ChIP Assay. A ChIP assay with HDAC1 was used after treat- FIG. 2. A and B , transactivation of CYP2B6 mRNA and a promoter assay by HDAC inhibitors in combination with TCPOBOP. Ym17 cells were exposed to HDAC inhibitors (500 M valproic acid, 1 mM phenylbutyrate, and 500 nM trichostatin A) with or without TCPOBOP (250 nM) for 24 h. mRNA expression of CYP2B6 was determined using real-time RT-PCR and normalized to GAPDH mRNA expression. Ym17 cells were transiently transfected with (NR1) 5 -tk-luciferase reporter construct. A, CYP2B6 mRNA expression. B, (NR1) 5 -tk-luciferase promoter assay. ‫,ء‬ P Ͻ 0.01 compared with control; #, P Ͻ 0.01 compared with HDAC inhibitors alone. C, effects of HDAC inhibitors on mRNA expression of CAR target genes in vivo. The CAR(ϩ/ϩ) and CAR(Ϫ/Ϫ) mice were given a single intraperitoneal injection of phenylbutyrate (1 g/kg) and TCPOBOP (1 mg/kg). The mice were then sacrificed, and their livers were collected and saved for analysis 6 h after intraperitoneal injection (n ϭ 5/treatment group). mRNA expression of the tested genes was determined using real-time RT-PCR and normalized to the ␤-actin mRNA expression. ‫,ء‬ P Ͻ 0.01. Ctrl, control; WT, wild-type; KO, knockout. ment with phenylbutyrate. The ChIP assay showed that the binding between HDAC1 and PBREM was inhibited by phenylbutyrate in Ym17 cells (Fig. 4) . TCPOBOP treatment augmented the binding between HDAC1 and PBREM. Phenylbutyrate treatment inhibited the TCPOBOP-augmented binding between HDAC1 and PBREM.
Discussion
This study has shown that HDAC inhibitors induce the expression of the CYP2B6 gene via a CAR-mediated pathway. Not only valproic acid but also other HDAC inhibitors including phenylbutyrate and trichostatin A induced CYP2B6 gene expression. Cerveny et al. (2007) showed that valproic acid up-regulates CYP3A4 gene expression via direct activation of the CAR pathway. Because all three HDAC inhibitors showed inducibility of CYP2B6, these inductions seem to be related to HDAC inhibition. Furthermore, HDAC inhibitors activated the CYP2B6 gene in synergy with TCPOBOP, a CAR agonistic ligand. Valproic acid was also reported to synergistically augment the effect of rifampicin in transactivation of CYP3A4 in primary human hepatocytes (Cerveny et al., 2007) .
In general, nuclear receptors bind to corepressors in their unliganded apoform with HDAC activity and act as transcriptional suppressors (Nagy et al., 1997; Hashimoto and Miyachi 2005) . With agonist ligand binding, a conformational change in the helix 12 of the ligandbinding domain creates an open conformation of the nuclear receptor holo-form that favors coactivator binding with histone acetyltransferase activity for its activation properties (Hashimoto and Miyachi, 2005) . Kim et al. (2000) reported that binding of CAR/RXR to the PBresponsive unit is accompanied by a loosening of the chromatin structure in the PB-responsive unit and that chromatin changes are induced in the proximal promoter region, which further disrupt the nucleosomal structure in rat CYP2B1/2. Such changes are probably mediated by coactivators of CAR/ RXR with histone-modifying activities, which affect chromatin structure and activate transcription (Kadonaga, 1998) , such as SRC-1. In the present study, the binding between coactivator SRC-1 and CAR was increased by HDAC inhibitors.
HDAC inhibitors did not affect the mRNA expression of UGT1A1, even though UGT1A1 is a CAR target gene (Sugatani et al., 2001 ). Activation of CAR target genes by HDAC inhibitors is specific for CYP2B6 but not for UGT1A1. Although the precise mechanism of this discrepancy is unknown, there are structural and functional differences in the enhancer region between CYP2B and UGT1A1. When the 290-bp PB-responsive enhancer module of UGT1A1 (gtPBREM) was compared with the 51-bp PBREM of the CYP2B genes, in the PBREM, two NR sites (NR1 and NR2) were found to reside close to each other, separated only by 18 bases that constitute the nuclear factor 1 binding site. On the other hand, there is no apparent nuclear factor 1 binding site in the gtPBREM. In the gtPBREM, three NR sites (NR4, gtNR1, and NR3) are equidistant from each other, separated by approximately 90 bases from the 5Ј-end of gtPBREM (Sugatani et al., 2001) . In sharp contrast to NR1, which is sufficient in itself for activation by CAR, gtNR1 could only be activated by the receptor in the context of 290-bp gtPBREM, and NR4 and NR3 seem to be essential for gtNR1 to confer its full enhancer activity. NR1 may be a much stronger enhancer and can be activated by CAR, whereas gtNR1 might be a weaker enhancer that requires additional factors for its activation. Cerveny et al. (2007) reported increased binding of CAR/RXR heterodimers to the DR3 element of CYP3A4 and to the DR4 element of MDR1 in the presence of valproic acid. On the other hand, binding of CAR/RXR to the ER6 element of CYP3A4 was not affected by valproic acid. Thus, structural and functional differences FIG. 3 . Effects of HDAC inhibitors on binding between HDACs, SRC-1, and CAR. A, binding between HDACs and CAR treated with HDAC inhibitors. Immunoprecipitation with tagged CAR. Ym17 cells were treated with HDAC inhibitors (500 M VPA, 1 mM PBA, and 500 nM TSA) for 1 h and were lysed in ice-cold immunoprecipitation buffer. His-tagged CAR was immunoprecipitated with antiHis antibody, and samples were subjected to a Western blot analysis with the indicated antibodies. After incubation with the secondary antibodies, the immunoreactive bands were visualized using an enhanced chemiluminescence system. B, binding between SRC-1 and CAR treated with HDAC inhibitors. After immunoprecipitation with tagged CAR, samples were subjected to a Western blot analysis with anti-SRC-1 antibody. C, siRNA knockdown of HDAC. A 12.5-pmol sample of HDAC siRNA or control siRNA was transfected into Ym17 cells in each well of six-well plates. After 24 h, the cells were treated with chemicals. mRNA expression of CYP2B6 was determined by real-time RT-PCR. siRNA knockdown of HDAC1 resulted in a significant increase in the CYP2B6 mRNA expression. ‫,ء‬ P Ͻ 0.01 .   FIG. 4 . The effects of HDAC inhibitors on HDAC1 binding to CAR response elements of CYP2B6 investigated with a ChIP assay. Ym17 cells were incubated with 1 mM phenylbutyrate and/or 250 nM TCPOBOP (TC) for 1 h. ChIP was performed by using a ChIP assay kit, according to the manufacturer's instructions. The DNA was amplified by real-time PCR using a specific primer set designed to the PBREM. The binding between HDAC1 and PBREM was inhibited by phenylbutyrate. TCPOBOP treatment augmented the binding between HDAC1 and PBREM. Phenylbutyrate treatment inhibited the TCPOBOP-augmented binding between HDAC1 and PBREM. ‫,ء‬ P Ͻ 0.01. in enhancer region may be related to the different responses to HDAC inhibitors.
No synergistic augmentation in transactivation of Cyp2b10 mRNA between phenylbutyrate and TCPOBOP was observed in vivo. One possibility is that Cyp2b10 mRNA induction by TCPOBOP (approximately 800-fold) may be the maximum attainable, resulting in the observed lack of synergistic activation by phenylbutyrate in mice. Another possibility is that the in vivo studies were done in the mouse with the Cyp2b10 gene, and the cell culture work was done with human cells and the CYP2B6 gene. Whereas human CAR and CYP2B6 share many common characteristics with their rodent counterparts, they also display their own specificities (Zelko and Negishi, 2000; Sueyoshi and Negishi, 2001 ). The differences between the human and mouse studies may have resulted in the differences in synergistic activation by phenylbutyrate. Further studies are needed to determine the precise mechanism of this discrepancy.
There are selectivities of inhibition by HDAC inhibitors, and valproic acid inhibits class I HDACs. As a result, we evaluated the interaction between CAR and class I HDACs in this study. The relations between other HDACs and CAR were not evaluated, and further studies may be needed to define the precise mechanism between HDACs and CAR.
In conclusion, HDAC inhibitors mediated the transactivation of the CYP2B6 gene via interaction with the nuclear receptor CAR. HDAC inhibitors disrupt the binding between HDAC1 and CAR. Thereafter, SRC-1 is recruited to the CAR complex, thus resulting in CARmediated CYP2B induction.
